anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/FR94/00143 Sec. 371 Date Oct. 23, 1995 Sec. 102(e) Date Oct. 23, 1995 PCT Filed Feb. 9, 1994 PCT Pub. No. WO94/18228 PCT Pub. Date Aug. 18, 1994A method for preparing an aqueous protein composition from human blood plasma, wherein the plasma undergoes a series of treatments by heating and precipitating agent to give albumin solutions containing the precipitating agent, and said precipitating agent is separated from the resulting solutions to give a crude aqueous albumin solution which is subjected to at least one liquid phase chromatography step to retain at least part of the secondary proteins other than albumin. The chromatography comprises affinity chromatography on a particulate support consisting of neutral particles loaded with at least one compound comprising sulphate groups, whereby, after the albumin solution has been fed through, the particulate affinity chromatography support is eluted by feeding through an aqueous saline solution, preferably by increasing the ionic strength, and the desired protein composition is collected by elution. A protein composition obtained by the method, an isolated glycoprotein having a molecular weight of 50,000+/-3,000 daltons and contained in the composition, an agent for stabilizing albumin during a Tyndall effect treatment, and an agent for detecting and/or assaying antibodies by ELISA or immuno-imprinting, are also provided.
Unhealthy alcohol use (UAU) is one of the leading causes of premature mortality among adults in the United States and has been increasing during the COVID-19 pandemic. UAU is more frequent among emergency department (ED) patients than in the general population and ED visits involving alcohol consumption have increased in recent years. Substance use has been described as the most important modifiable health behavior in the ED, and the ED has been highlighted as a key setting to intervene with UAU individuals. Consequently, health systems across the country need low burden, scalable ways to intervene with individuals but often have limited time and resources. Mobile technologies have been suggested as a solution to assist EDs in addressing UAU and one of the lowest burden, scalable approaches are text messaging interventions. Text messaging interventions for ED and trauma patients and other populations have shown good outcomes, including reductions in drinking quantity and frequency. Despite strong research support and promise for scalability, there is little evidence that technology-based behavioral health interventions can be effectively implemented into healthcare settings. There are few studies in which technology interventions for behavioral health are put into real world healthcare settings; those that have been conducted show that the benefits seen in randomized trials are often not realized. While EDs are promising venues for addressing UAU using text messaging interventions, the process of providers making them available to patients in an efficient way within already busy and overburdened ED workflows (i.e., implementation in real-world ED settings) and patients adopting them remains a new area of research. This proposal builds on the longstanding collaboration of our interdisciplinary team on the implementation of substance use screening and brief interventions in healthcare settings. In response to the NIH Notice of Special Interest for Research in the Emergency Setting, the investigators propose to examine potential barriers and facilitators to staff offering and patients accepting a text messaging intervention in the ED. The investigators will then use a stakeholder-engaged Intervention Mapping process to develop a multi-component implementation strategy for EDs. Finally, the investigators will conduct a mixed method 2-arm cluster-randomized pilot study in 4 EDs that serve \~13,000 UAU patients per year to assess the feasibility, acceptability and preliminary effectiveness of the implementation strategy. The Integrated Promoting Action on Research Implementation in Health Services (i-PARIHS) framework will guide study activities. Low burden technology, like text messaging, along with targeted implementation support and strategies driven by identified barriers and facilitators could sustain large-scale ED-based alcohol screening programs and provide much needed support to patients who screen positive while reducing burden on EDs. The proposed study would be the first to develop and test this targeted implementation strategy. This 2-year R21 will prepare for a future, larger, fully-powered hybrid effectiveness-implementation trial.
A process registers, at the user mobile computing device, one or more health-related documents for inclusion in a cloud-based digital health wallet. Furthermore, the process receives, at a user mobile computing device, a biometric identification input from the user for the registration of the one or more health-related documents. The process sends, from the user mobile computing device to a server computing device that stores the cloud-based digital health wallet, a first coded version of the biometric identification input for storage in a biometric validation data structure. Additionally, the process determines, at the user mobile computing device, a location of the user. Moreover, the process sends, from the user mobile computing device to the server computing device, a validation request at the location. The validation request includes a second coded version of a subsequently inputted biometric input from the user at the location.
Bladder cancer is a common tumor that impacts the urinary system and marked by a significant fatality rate and an unfavorable prognosis. Promising antineoplastic properties are exhibited by brusatol, which is obtained from the dried ripe fruit of Brucea javanica. The present study aimed to evaluate the influence of brusatol on the progression of bladder cancer and uncover the molecular mechanism involved. We used Cell Counting Kit-8, colony formation and EdU assays to detect cell numbers, viability and proliferation. We used transwell migration assay to detect cell migration ability. The mechanism of brusatol inhibition of bladder cancer proliferation was studied by flow cytometry and western blotting. It was revealed that brusatol could reduce the viability and proliferation of T24 and 5637 cells. The transwell migration assay revealed that brusatol was able to attenuate the migration of T24 and 5637 cells. We found that treatment with brusatol increased the levels of reactive oxygen species, malondialdehyde and Fe2+, thereby further promoting ferroptosis in T24 and 5637 cells. In addition, treatment with RSL3 (an agonistor of ferroptosis) ferrostatin-1 (a selective inhibitor of ferroptosis) enhanced or reversed the brusatol-induced inhibition. In vivo, treatment with brusatol significantly suppressed the tumor growth in nude mice. Mechanistically, brusatol induced ferroptosis by upregulating the expression of ChaC glutathione-specific gamma-glutamylcyclotransferase (Chac1) and decreasing the expression of SLC7A11 and Nrf2 in T24 and 5637 cells. To summarize, the findings of this research demonstrated that brusatol hindered the growth of bladder cancer and triggered ferroptosis via the Chac1/Nrf2/SLC7A11 pathway.
Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
Lacrimal drainage obstruction can manifest as epiphora or recurrent infections with mucopurulent discharge and may even cause social embarrassment. Obstruction can occur at any level along the lacrimal drainage system: punctum, canaliculus, nasolacrimal duct, or nasal ostium. It is seen more often in females, especially in postmenopausal women. The etiopathogenesis of lacrimal passage obstruction appears to be multifactorial. Chronic inflammation has been suggested to be the most causal. Dacryocystorhinostomy (DCR) is a standard surgical procedure used to treat nasolacrimal duct obstruction (NLDO), with a reported success rate of more than 90%.

Knowledge concerning the morphological characteristics of lacrimal passage obstruction using traditional diagnostic methods (e.g., lacrimal irrigation, probing, dacryocystography) is limited. Dacryoendoscopy was originally described in 1979 and has recently matured for use in lacrimal drainage system imaging. It has been proved to be a useful instrument not only for understanding differences in the etiology of obstructions but also for treating LD obstructions. On the other hand, semiconductor diode laser can achieve more effective tissue dissection than direct probing technique with minimal hemorrhage and improved intraoperative view. Hence, dacryoendoscopic-assisted laser dacryoplasty with silicone intubation (DLDI) offers direct therapy to the obstructed site, leading to minimal collateral damage external to the target zone. In addition, this procedure can be performed under local anesthesia as an outpatient procedure in the office, and it has advantages such as short surgery time and less risk of bleeding during surgery, resulting in its increasingly widespread use in China. Although the silicone intubation using dacryoendoscopy has increased the success rates, the success rates vary from a low of 51% to a high of 90%. The difference in success rates seems to depend on the site of obstruction, differences in the surgical technique, stringency of definitions of success, and duration of follow-up.

A greater understanding of factors associated with treatment failure may allow us to glean insights regarding patient selection and ultimately improve treatment outcome. The aim of our study was to report the results of DLDI for the management of NLDO, and to identify factors associated with DLDI failure.
Treatment will be administered in two phases, an induction and a maintenance phase. Subjects will continue induction treatment for up to 1 year. Those who have a CR in the induction phase will enter the maintenance phase of the study. Subjects who experience ongoing SD or an ongoing PR at 1 year may enter the maintenance phase at the Investigator's and Sponsor's discretion. Subjects may remain in the maintenance phase of the study for up to 1 year. Treatment in the study will be discontinued if the subject experiences confirmed PD or unacceptable toxicity (not corrected with dose reduction), withdraws consent, undergoes liver transplantation or surgical resection, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. Subjects with an initial assessment of PD may, at the discretion of the Investigator, continue to receive study treatment until PD is confirmed. The maximum time on study treatment is 2 years.
INTRODUCTION: The management of relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) has witnessed dramatic changes in the recent past. Despite the availability of multiple novel immunotherapies in R/R setting, there remains an unmet need for off-the-shelf therapies, particularly in patients with primary refractory, multiply relapsed disease or those experiencing cellular immunotherapy failure. To harness the power of the T-cell mediated immunity, a novel class of drugs called bispecific antibodies (BsAbs) have been developed. These BsAbs are currently under investigation both in frontline and R/R setting and hold the potential to revolutionize the management of LBCL.
AREAS COVERED: This review article summarizes the currently available BsAbs, their mode of action, efficacy, and safety data for untreated and R/R LBCL. In addition, the role of these BsAbs in combination with currently available chemoimmunotherapy regimens is also discussed.
EXPERT OPINION: Two BsAbs have secured FDA approval for R/R LBCL, with expected approval of more BsAbs (including in earlier treatment lines). These drugs provide a highly efficacious and relatively safe treatment option for patients with highly pretreated disease including relapse after cellular immunotherapies. In addition, these BsAbs provide a platform for chemotherapy-free regimen for older/frail patients.
Brain imaging now allows to study non-invasively cognitive learning processes. An area of strong scientific interest is the development of executive control, an essential cognitive domain for academic and professional success and for mental and physical health. These functions are essentially located within the prefrontal cortex, characterising by a late maturation until the end of adolescence and, while under genetic control, can likely be improved with targeted interventions. The objective of this project is simple and innovative: testing in adolescents with the most appropriate brain imaging technologies available today (the Magnetic Resonance Imaging, MRI), the effect of an executive training focused on the inhibitory control (IC). This project aims at precisely testing the effect at the cognitive and brain levels of IC training in adolescence. To do this, the investigators will recruit two groups of 30 teenagers aged 16 to 17 years old, each assigned to one of two learning situations: IC vs Active Control (AC). Each participant will participate in 25 training sessions of 15 minutes per day, 5 days a week for a month. Brain structural and functional differences in the brain and between the pre-test and post-test related to intense IC training will be correlated with cognitive progress.
The present invention relates to a cosmetic composition for skin whitening using dendropanax morbifera ferment extract. The composition is characterized by comprising: 500±50 weight parts of dendropanax morbifera ferment extract; and 100±50 weight parts of oriental medicine material wherein purple sweet potato, mung bean, adlay, gastrodia, potato, Opuntia humifusa, propolis, and Glechoma longituba are mixed. The composition comprises: 1-70 wt% of the dendropanax morbifera ferment extract and the oriental medicine material; and, as its remains, 1-5 wt% based on a total weight of the composition and a cosmetic base. Accordingly, the present invention forms the skin whitening cosmetic composition using dendropanax morbifera ferment extract and oriental medicine material. Thereby, the present invention has excellent effectiveness of skin whitening by inhibiting tyrosinase activities through active ingredients of the dendropanax morbifera ferment extract and the oriental medicine material, and additionally, excellent effects in stability, moisturizing, improving wrinkles of the skin. Furthermore, the present invention can be utilized in lotion, skin, serum, essence, mask pack, UV cream, BB cream, powder, handwash and the like, and active ingredients of the dendropanax morbifera ferment extract and the oriental medicine material can be safely used without side effects with respect to the skin, and thereby, having effects of excellent stability of a product.
The invention discloses a capsule for enhancing bone mineral density, and a preparation method thereof. The capsule comprises the components of, by weight, 33.25 parts of glucosamine hydrochloride, 31.25 parts of calcium carbonate, 20.75 parts of rhzizoma drynariae, 12.5 parts of microcrystalline cellulose and 2.25 parts of silica powder. The capsule for enhancing the bone mineral density can reach an effect for enhancing the bone mineral density. The capsule is prepared by scientific and reasonable production process according to a health-care theory for increasing the bone mineral density, by using the glucosamine hydrochloride, the calcium carbonate and the rhzizoma drynariae are used as main raw materials. The product has a definite function and controllable quality and is safe for taking. The preparation method of the capsule for enhancing the bone mineral density is simple and can finish the preparation of the capsule by a common apparatus.
All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
One of the aspects of the present invention relates to a method for the treatment of retinal detachments utilizing a transparent liquid or gel retina reattachment enhancing material preferably perfluorotri-n-propylamine for long-term but not permanent replacement in the eye for effecting a retinal reattachment of a retinal tear. A sufficient amount of a gas is first injected into the vitreous cavity of a patient's eye having a first gel or liquid material therein and a retinal tear so that the gas expands, compresses, and displaces an amount of the first gel or liquid to provide a space for receipt of a sufficient amount of the retina reattachment enhancing material. Once sufficient space is provided in the vitreous cavity, the retina reattachment enhancing material is injected into the eye. Once the retinal tear is visible and lies flat upon the underlying tissue, the retina is tacked down around the retinal tear so as to form a retinal scar. The enhancing material is left in the eye until the retinal tear is fixedly reattached to the underlying tissue. The enhancing material which is preferably a liquid perfluorocarbon material should not remain indefinitely in the eye and is removed and replaced with a replacement material that can be left in the eye indefinitely. Outpatient procedures are emphasized.
OBJECTIVE: The purpose of this study is to evaluate the safety and efficacy of linaclotide and polyethylene glycol (PEG) electrolyte powder in patients with chronic constipation undergoing colonoscopy preparation.
PATIENTS AND METHODS: We included 260 patients with chronic constipation who were scheduled to undergo a colonoscopy. They were equally divided into 4 groups using a random number table: 4L PEG, 3L PEG, 3L PEG+L, and 2L PEG+L. The 4 groups were compared based on their scores on the Boston Bowel Preparation Scale (BBPS) and Ottawa Bowel Preparation Quality Scale (OBPQS), adverse reactions during the bowel preparation procedure, colonoscope insertion time, colonoscope withdrawal time, detection rate of adenomas, and their willingness to repeat bowel preparation.
RESULTS: In terms of the score of the right half of the colon, the score of the transverse colon, the total score using BBPS, and the total score using OBPQS, the 3L PEG (polyethylene glycol)+L group was superior to groups 3L PEG and 2L PEG+L ( P <0.05), but comparable to the 4L PEG group ( P >0.05). The incidence rate of vomiting was higher in the 4L PEG group than in the 2L PEG+L group ( P <0.05). There was no statistically significant difference in the insertion time of the colonoscope between the 4 groups. The colonoscope withdrawal time in the 3L PEG+L group was shorter than in groups 4L PEG and 3L PEG ( P <0.05) and comparable to that in the 4L PEG group ( P >0.05). There was no statistically significant difference in the rate of adenoma detection among the 4 groups ( P >0.05). The 4L PEG group was the least willing of the 4 groups to undergo repeated bowel preparation ( P <0.05).
CONCLUSION: The 3L PEG+L is optimal among the 4 procedures. It can facilitate high-quality bowel preparation, reduce the incidence of nausea during the bowel preparation procedure, and encourage patients to undertake repeated bowel preparation.
Participants in the contingency management (CM) treatment arm will receive the usual care (UC) treatment program offered at the Tobacco Treatment Research Program (TTRP) and will be eligible to earn gift cards at each weekly visit on their quit date up until four weeks post-quit for proof of abstinence. They will earn $20 in gift cards for quitting on the specified quit day (i.e., one week after the orientation visit), and this amount will increase by $5 with each successive weekly abstinent visit (i.e., up to $40 in gift cards at 4 weeks post-quit; up to $150 total).
BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment with oral anticoagulation is of uncertain benefit.
METHODS: We conducted a trial involving patients with subclinical atrial fibrillation lasting 6 minutes to 24 hours. Patients were randomly assigned in a double-blind, double-dummy design to receive apixaban at a dose of 5 mg twice daily (2.5 mg twice daily when indicated) or aspirin at a dose of 81 mg daily. The trial medication was discontinued and anticoagulation started if subclinical atrial fibrillation lasting more than 24 hours or clinical atrial fibrillation developed. The primary efficacy outcome, stroke or systemic embolism, was assessed in the intention-to-treat population (all the patients who had undergone randomization); the primary safety outcome, major bleeding, was assessed in the on-treatment population (all the patients who had undergone randomization and received at least one dose of the assigned trial drug, with follow-up censored 5 days after permanent discontinuation of trial medication for any reason).
RESULTS: We included 4012 patients with a mean (±SD) age of 76.8±7.6 years and a mean CHA2DS2-VASc score of 3.9±1.1 (scores range from 0 to 9, with higher scores indicating a higher risk of stroke); 36.1% of the patients were women. After a mean follow-up of 3.5±1.8 years, stroke or systemic embolism occurred in 55 patients in the apixaban group (0.78% per patient-year) and in 86 patients in the aspirin group (1.24% per patient-year) (hazard ratio, 0.63; 95% confidence interval [CI], 0.45 to 0.88; P = 0.007). In the on-treatment population, the rate of major bleeding was 1.71% per patient-year in the apixaban group and 0.94% per patient-year in the aspirin group (hazard ratio, 1.80; 95% CI, 1.26 to 2.57; P = 0.001). Fatal bleeding occurred in 5 patients in the apixaban group and 8 patients in the aspirin group.
CONCLUSIONS: Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).
Disclosed is a method for producing a fine powder. Two or more kinds of original materials are suspended and liquefied inert gas to form two or more kinds of slurries wherein each slurry contains at least one or more different kinds of original materials. Granular dry ice grinding medium is put into the slurries. The slurries are individually stirred and the original materials are pulverized into submicron-sized or nano-sized particles in the liquefied inert gas. The slurries are thereafter mixed. The liquefied inert gas is vaporized and the granular dry ice is sublimated. A mixture of the particles of the two or more kinds of original materials is recovered.
The invention relates to application of Houttuynoid E in preparation of a drug for promoting small bowel peristalsis. The invention discloses the application of Houttuynoid E in preparation of the drug for promoting small bowel peristalsis. According to the pharmacological experiment, the Houttuynoid E has good effect of promoting small bowel peristalsis. The use of the Houttuynoid E disclosed by the invention in the preparation of the drug for promoting small bowel peristalsis is firstly disclosed. The framework type is a brand-new framework type and has an unexpected strong effect of restraining the bacterial activity, and so the Houttuynoid E is impossibly reveled by other compounds, and has outstanding substantial characteristics. Meanwhile, the Houttuynoid E has significant progress in preparing the drug for promoting small bowel peristalsis.